---
title: R/Pharma summit
subtitle: The in-person event
listing:
  sort: "date desc"
  contents: "posts"
  sort-ui: false
  filter-ui: false
  categories: true
  feed: true
page-layout: full
#margin-header: signup.html
title-block-banner: "#EDF3F9"
title-block-banner-color: body
search: false
---

## Prior summits

This document captures discussion, pain points and a path to next steps discussed at R/Pharma Summits.

::: {.callout-note icon=false}

## {{< fa users >}} 2024 F2F Roundtables in Seattle

~120 leaders from 40+ companies met F2F in Seattle for a series of
discussions on the most pressing topics for late-stage reporting in R. 

The discussion was crowdsourced via a github discussion, and led to the 
following topics:

- [Transitioning our people from SAS to R](/summit/posts/2023-change-mgt.html)
- [How best to engage and enable small/mid-size pharma to use R and open source tools](/summit/posts/2024-small-mid-pharma.html)
- [Future core competency of clinical statistical programmer with AI/LLM](/summit/posts/2024-ai.html)
- [Can we do data storage and processing better in clinical trials?](/summit/posts/2023-dataformat.html)
- [Sharing R data products externally](/summit/posts/2024-rproducts.html)
- [Validation of shiny apps](/summit/posts/2024-shiny-validation.html)
- [R package validation](/summit/posts/2024-r-pkg-validation.html)
- [Leveraging operational metrics for better SCEs/platforms](/summit/posts/2023-sce.html)

:::

::: {.callout-note icon=false}

## {{< fa users >}} 2023 F2F Roundtables in Chicago

~60 leaders from 40+ companies met F2F in Chicago for a series of
discussions on the most pressing topics for late-stage reporting in R. 

The discussion was crowdsourced via a github discussion, and led to the 
following topics:

- [What are our goals for a modern clinical reporting workflow, on a modern SCE?](/summit/posts/2023-sce.html)
- [What are the risks with our increasing external business code dependencies?](/os-depends.html)
- [We have a path to R package validation - but what are we doing with shiny apps?](/summit/posts/2024-shiny-validation.html)
- [What is the path to an interactive CSR?](/summit/posts/2024-shiny-validation.html)
- [The case for contributing to OS](/summit/posts/2023-case-os.html)
- [Where are we with our people?](/summit/posts/2023-change-mgt.html)
- [What should we be doing to leverage advances in LLMs/AA/AI impact? (at the drug development through to developer efficiency levels)](/summit/posts/2024-ai.html)
- [What are the barriers bringing imaging/genomics/digital biomarkers and the CRF closer?](/summit/posts/2023-multi-modal.html)

:::

::: {.callout-note icon=false}

### {{< fa graduation-cap >}} References

[CAMIS - comparing differences based on tool used](https://psiaims.github.io/CAMIS/)

[PHUSE Open Source guidance](https://phuse-org.github.io/E2E-OS-Guidance/)

### 2024

[R Validation Hub update](https://pharmar.github.io/events-positconf2024/#/title-slide)

[2024 planning repo](https://rinpharma.github.io/rinpharma-summit-2024/)


### 2023

[R Validation Hub update](https://pharmar.github.io/events-rpharma2023/)

[Doug's slides on the shared validated repo](https://pharmar.github.io/events-positconf2023/#/title-slide)

[2023 planning repo](https://rinpharma.github.io/positconf-roundtables-2023/)


:::

## Summit discussions
